Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Lonza Group    LONN   CH0013841017

LONZA GROUP (LONN)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/16/2018 01/17/2018 01/18/2018 01/19/2018 01/22/2018 Date
267.4(c) 269.8(c) 265.3(c) 270.2(c) 271 Last
283 290 350 562 352 017 480 807 218 254 Volume
+1.13% +0.90% -1.67% +1.85% +0.30% Change
More quotes
Financials ( CHF)
Sales 2017 5 099 M
EBIT 2017 896 M
Net income 2017 485 M
Debt 2017 3 967 M
Yield 2017 1,06%
Sales 2018 6 077 M
EBIT 2018 1 208 M
Net income 2018 751 M
Debt 2018 3 531 M
Yield 2018 1,26%
P/E ratio 2017 39,83
P/E ratio 2018 28,13
EV / Sales2017 4,72x
EV / Sales2018 3,89x
Capitalization 20 121 M
More Financials
Company
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products.It operates through the following segments: Pharma&Biotech, and Specialty Ingredients.The Pharma&Biotech segment deals with the supply of pharmaceutical ingredients and biopharmaceuticals as well as... 
More about the company
Surperformance© ratings of Lonza Group
Trading Rating : Investor Rating :
More Ratings
Latest news on LONZA GROUP
01/08 LONZA : Showcases Actives that Help Protect Skin Against Lifestyle and Environme..
2017 LONZA : Serialization Capabilities Now Operational at Lonza Edinburgh Facility f..
2017 LONZA : to Showcase Its Latest Solutions for Enhanced QC Testing and Transfectio..
2017 LONZA : Akouos and MEE Announce Strategic Gene Therapy License Agreements on Hea..
2017 LONZA : New Plastics Laboratory Opening at the Lonza Innovation and Technology C..
2017 LONZA : Announces New Offering of Silensomes HLM for Drug Metabolism Studies
2017 LONZA : Launches XS™ Pichia 2.0 Expression and Manufacturing Platform for ..
2017 LONZA : Announces New Offering of Silensomes™ HLM for Drug Metabolism Stud..
2017 Prosecutors search Metro offices in insider trading probe
2017 LONZA : Expands Service Offerings for Early Phase Biopharmaceutical Drug Develop..
More news
Sector news : Biotechnology & Medical Research - NEC
08:48a Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion
08:48a Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion
08:48a SANOFI : Nears Deal for Bioverativ -- WSJ
08:47a Sanofi to buy U.S. haemophilia group Bioverativ for $11.6 billion
07:47a SANOFI : to Acquire Bioverativ for $11.6 Billion
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01/04Global Bio CMO Market: Size, Trends & Forecasts (2018-2022) with Lonza Gr.. 
01/04Global Bio CMO Market: Size, Trends & Forecasts (2018-2022) with Lonza Gr.. 
01/04Global Bio CMO Market: Size, Trends & Forecasts (2018-2022) with Lonza Gr.. 
2017Pharmaceutical Microbiology 22nd & 23rd January 2018 Holiday Inn Kensingt.. 
2017Pharmaceutical Microbiology 22nd & 23rd January 2018 Holiday Inn Kensingt.. 
More tweets
Qtime:35
News from SeekingAlpha
2017 Oppenheimer International Growth Fund Inst (OIGYX) November Summary
2017 Oppenheimer International Growth Fund Inst (OIGYX) October Summary
2017 Oppenheimer International Growth Fund Inst (OIGYX) September Summary
2017 Oppenheimer International Growth Fund Inst (OIGYX) August Summary
2017 Oppenheimer International Growth Fund Inst (OIGYX) July Summary
Chart LONZA GROUP
Duration : Period :
Lonza Group Technical Analysis Chart | LONN | CH0013841017 | 4-Traders
Technical analysis trends LONZA GROUP
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 283  CHF
Spread / Average Target 4,8%
EPS Revisions
Managers
NameTitle
Richard Ridinger Chief Executive Officer
Rolf Soiron Chairman
Rodolfo Savitzky Chief Financial Officer
Patrick Aebischer Vice Chairman
Jean-Daniel Gerber Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP2.62%20 876
CELLTRION, INC.--.--%33 774
IQVIA HOLDINGS INC2.37%21 423
INCYTE CORPORATION-4.65%19 660
ALNYLAM PHARMACEUTICALS, INC.-1.42%12 275
NEKTAR THERAPEUTICS16.21%11 273